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To assess the long-term changes in cardiac function iu N 
tomatic patients with severe left veatricuiar dysfunction, left 
ventricular (clneangiography) and right ventricular (radionuelide 
angiography) function were assesxd at baseline in 49 patients 
enrolled in the prevention arm of the Studies of Left Ventricular 
Dysfuoction. After an average follow-up eriod of 12.4 months, 30 
patients (11 randomized to the placebo group and 19 to the 
enalapril group) could be restudied to assess the progression of
ventricular dysfnnction. After 1 year of follow-up, the changes in
beart rate, left ventricular end=diastolic and systolic pressure and 
right ventricular volumes were comparable in both groups. How- 
ever, there were modest but opposite changes in left ventricular 
end-diastolic volome (+9 ml/m* with placebo vs. -10 ml/m* with 
- 
Confronted with a pressure or volume overload or a partial 
destruction of its wall, the heart has many adaptive mecha- 
nisms at its disposal to maintain cardiac output compatible 
with survival. At the cellular level (myocyte, fibroblast, 
microvasculature), complex biochemical transformations i - 
tervene, triggered by mechanical nd neurohumoral stimuli 
(l-3). However, the heart is more than a collection of cells: 
it is a highly organized organ, composed offour cavities and 
the pericardium and integrated in the cardiovascular loop 
(4). Thus, to understand the changes in left ventricular 
function (for example, after myocardial infarction or in 
idiopathic dilated cardiomyopathy), the consequences of 
microscopic changes (cellular level) must also be considered 
at the level of the organ itself. 
In this respect, he repercussion f these cellular changes 
on the radius of curvature of the cavity, wall thickness and 
diastolic wall stitfness is particularl-i important (1,2,5). A 
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edapril, p C 0.05) and end-systolic vohune (+5 ml/m* with 
PLarebo vs. -13 din* with endapril, p C 0.05). Mean systolic 
wall stress inc& inti@m!ly in both groups, whereas 
ejection fraction increased from 29% to 31% in the placebo group 
and from 28% to 32% with enalapril (p = NS, pk~& VS. 
enalaprilj. 
Even in asymptomatic patients with severe l ft ventrlcuiar 
dysftmetton, there was a slow progre&m of left ventricular 
dilation. Enalapril administration appeared to slow this progres- 
sion, but wall stress wa8 not nomalized by the treatment at the 
doses used in the study, indicating that at least one of the _&inudi 
for tiwther remodeling maained present. 
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wealth of information about here changes inleft ventricular 
shape and wall structure during the acute and subacute 
phases after myocardial infarction has been accumulated 
(1,2,6-8). However, less is known about he changes in left 
ventricular function occurring during the late phase and, to 
our knowledge, few studies have simultaneously examined 
the changes in right and left ventricular function. 
The Studies of Left Ventricular Dysfunction (SOLVD) 
offered an opportunity to study the long-term changes in 
cardiac function occurring in patients with long+Xandii, 
severe ventricular dysfwrction. Recently, the changes inleft 
ventricular function evidenced in SOLVD in patients with 
congestive heart failure have been reported (9). The purpose 
of this study is to describe the change8 noted in patients with 
asymptomatic ventricular dysfunction at baseline. BY com- 
bining this information with that from other eports (1;2,6,7), 
it becomes possible to propose a hypothesis explaining the 
long-term changes in wall thickness, wall volume and ejec- 
tion fraction in this setting. 
Methods 
Stiy patients. The SOLVD protocol has been described 
in detail (10,ll). Briefly, patients were eligible if they were 
between 21 and 80 years of age, had a left ventricular ejection 
fraction 135% and were not receiving an angiotensh- 
converting enzyme inhibitor. The patients had to be in a stable 
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clinical ~0itditi011, free of noncardiac life-threatening disease 
and without a myocardii i&rction in the past 30 days. m 
p&m gave written informed consent to participate in the 
study, which was approved by the Ethics Committee ofeach 
participating institution. According to their symptomatic sta- 
tus, patients were stmtied to the treatment arm if they wefe 
already being treated for heart fsihrre or to the prevention arm 
iftheywere~~~inNewYarkHeartAssociationfunctional 
classIM1Iwhodidnotreq~therapyf~beartEdilure 
(11,12). After baseline measurements, patients were random- 
ized to either placebo r eoalapril(2.5 to10 mg twice MY) 
therapy. The data repotted here concern a subset of49 patients 
in the prevention arm studied at the St. Luc University 
Hospital. There were 42 men and 7 women with a mean age of 
56.1 + 9.9 years. The etiology of left ventricular dysfunction 
was ischemic heart disease in44 patients and idiopathic dilated 
cardiomyopathy in 5patients (Table 1). 
Data equlsltlon a d analysis. Radionuclide mgiogrupfzy. 
To assess right ventricular volumes, gated equilibrium radio- 
nuclide ventriculography was performed with the patient 
supine on the day of left heart catheterization. AU subjects 
received 10 mg of intravenous sodium pyrophosphate and 
1.8 mg of stannous chloride, followed 30 min later by 20 mCi 
of technetium99m pertechnetate to achieve red cell labeling. 
Gated equilibrium radionuclide data were acquired using a 
mobile Apex 215 M camera (Elscint) with a low energy, 
all-purpose, parallel hole collimator. The camera was posi- 
tioned in a left anterior oblique projection with caudal 
angulation, allowing the best separation between ventricles 
and atria. The data gated to the patient’s electrocardiogram 
(ECG) were acquired in frame mode, using 32 frames/cycle 
and 64 X 64 pixel matrix. RadionuclZe studies were ana- 
lyzed at a core facility at Tufts University, New England 
Medical Center, using previously described methods (9,13). 
Contrast venJr~cu&rapfry. Left heart catheterization 
was performed with patients in the fasting state and without 
premeditation asdescribed previously (14). An 8F pigtail 
Millar catheter was introduced through the femoral artery to 
measure hii fidelity left ventricular pressure and to inject 
contrast material. Angiographic images were acquired with 
Philips Polydiinost C and DVI systems. These systems 
allow the acquisition of nonsubstracted l ftventricular im- 
ages at 50 frames/s with 1.024 shades of gray (10 bits) and a 
geometric resolution of approximately 0.7 mm. During the 
3 ms of rame exposure, there is simultaneous acquisition of
left ventricular p essure and the ECG signal (15). 
Left ventricuhr pressure, together with the ECG signal, 
was continuously recorded on analog magnetic tape (Honey- 
well 101). Analog data were digitized every 2 ms and 
processed off-line with a Hewlett-Packard A900 computer. 
Specific points of the signals (such as the peak of the R wave 
or the lelt ventricular end-diastolic pressure) were automat- 
icdY detected by a set of subroutines. Left ventricular 
Pressure data after the peak first derivative ofleft ventricular 
Pressure (dP/dt) were also fitted to an exponential relation, 
using a least squares regression technique, and the time 
constant T, (0 to 40 ms after peak negative dP/dt) of this 
relation were used as indexes of left ventricular relaxation 
(16). As isovolumetric indexes of inotropic state, we used 
maximal dP/dt and dP/dt measured and normalized at a 
developed pressure of 40 mm Hg. For evaluation of left 
ventricular function, masked ventricular silhouettes were 
outlined frame by frame on a video screen using a joystick. 
Both premature and postpremature b ats were excluded 
from analysis. A computer system (APU Philips) derived the 
correction factor for X-ray magnillcation and calculated 
volumes every 20 ms by applying Simpson’s rule. 
Ejection fraction was calculated according to the classical 
formula, using the frame with the maximal pressure/volume 
ratio as end-systole (17). Volume data were corrected for 
body surface area. Myocardial wall thickness was deter- 
mined on the last diastolic frame and was computed for 
subsequent frames assuming a constant left ventricular 
mass. Left ventricular wall stress was computed using the 
formula of Mirsky (18); mean systolic wall stress was ob- 
tained by averaging data from the start of ejection to 
end-systole and mean diastolic stress was calculated by 
averaging data from end-systole tothe peak of the R wave. 
A lefi ventricular pressure-volume loop was constructed 
after data smoothii for each patient. 
Radionuclide angiography and lefi heart cathetetition 
were repeated after an average interval of 12.4 months in 30 
patients. Death, heart ransplantation or ew cardiac events 
(such as atria1 fibrillation) precluding a meaningful interpre- 
tation of the changes in left ventricular function occurred 
during the follow-up eriod in 8 (36%) of 22 patients in the 
placebo group and 4 (15%) of 27 patients in the enaiapril 
group (Table 1). Three patients in the placebo group and 
three in the enalapril group refused the second study and one 
in the enalapril group was not restudied because acquired 
immune deficiency syndrome (AIDS) had been diagnosed 
during the interval. 
Statlstieal analysis. The data are presented as mean value 
f SD. To assess treatment effects, the differences between 
baseline and follow-up studies were calculated in the placebo 
group and enalapril group and were compared by the Mann- 
Whitney U test. 
Results 
Table 2 presents the left ventricular function variables 
and right ventricular volumes at baseline and after 1 year of 
follow-up. In the placebo group, end-diastolic and end- 
systolic volumes increased during the follow-up eriod by 
6% and 5%, respectively, whereas inthe enalapril group, the 
corresponding volumes decreased by 7% and 12%. These 
modest but opposite changes in left ventricular volumes 
were the only changes reaching statistical diierence be- 
tween the groups. Right ventricular end-diastolic volume 
increased insignificantly in the placebo and enalapril groups 
(by 3% and 6%, respectively); left and right ventricular 
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Table 1. Clinical Characteristics of the Patients at Baseline and I Year After Randomization: Prevention Arm of SOLVD 
45/M 
64/M 
46/M 
67/M 
3slM 
64/M 
68&I 
4OlM 
57&l 
xi/F 
6liM 
66/M 
62/M 
55/M 
59/M 
6lAU 
69/M 
6WF 
57iF 
64&l 
59/F 
36/M 
NYHA 
I 
I 
I 
II 
II 
I 
II 
II 
I 
II 
I 
II 
I 
I 
I 
II 
1 
1 
II 
I 
II 
II 
Etiology 
AM1 
AM1 
AM1 
AMI 
AM1 
AM1 
AMI, IMI 
IDCM 
IMI 
AM1 
IMI 
AM1 
IMI 
IMI 
IMI 
IHD 
AMI, IMI 
AM1 
AM1 
IMI 
IMI 
IHD 
Therapy 
PIaceWEnalapril 
Daily Dose 
NYHA Therapy (mpi Events 
Placebo Group (n = 22) 
.-~ 
VSD, AP 
VSD. CCB. AP 
VSD, CCB, AP 
II VSD. AP 20 
VSD. AP, AA 
VSD, AP 
VSD, AP 
I 
II 
I 
VSD, CCB, AP 
DIU. VSD, CCB, AP 
m 
20 
0 
VSD 
AP 
II 
II 
I 
II 
II 
II 
II 
AP 
AP 
DIU, VSD 
DGX, DIU. VSD, AP 
DGX. DIU 
m 
20 
20 
20 
20 
5 
20 
VSD, CCB, AP 
VSD 
VSD. CCB, AP 
VSD. CCB, AP 
VSD. CCB, AI’ 
VSD, CCB, AP 
VSD 
I AP 
II DGX. DIU. I?? 
I DIU, VSDF AP 
I VSD, CCB. AP 
II VSD. Al’ 
I AP 
II VSD, CCB. AP 
II DIU, AP 
20 
50 
0 
20 
20 
20 
0 
0 
Refuse4i restudy 
AFib 
Died 
CABG 
Refused restudy 
Refused restudy 
CAL3 
HTX 
Enalapril Group (n = 22) 
39hl II 
SO/-M I 
67lM I 
48/F II 
37/M I 
57/M I 
69/M II 
59/M 1 
63/M I 
45/M II 
53/M I 
56/M II 
58/M I 
62lM II 
57lM I 
63/M I 
60/M II 
63/M I 
42/M 1 
39/F II 
50/M 1 
67/M I 
44&I I 
68/F I 
58/M II 
57/M I 
63/M I 
AM1 
AM1 
AM1 
IDCM 
AM1 
AM1 
IMI 
AM1 
AMI 
IDCM 
IMI 
AMI. IMI 
AMI 
MI 
IMI 
AMI 
IHD 
AMI 
IMI 
IDCM 
AMI. IMI 
AM1 
AM1 
IDCM 
IMI 
IMI 
AMI, IMI 
CCB, AP 
VSD, CCB, AP 
VSD. AI’ 
VSD. CCB. AP 20 
VSD, CCB, AP 20 
AP 20 Refused restudy 
Died 
AP 
VSD, AP 
VSD. CCB, AP 
AP 
VSD, AP 
II 
I 
II 
I 
I 
I 
I 
II 
II 
I 
I 
I 
I 
I 
II 
II 
I 
II 
I 
III 
I 
I 
I 
I 
VSD. AP 
20 
20 CABG 
Died 
VSD. AP 
VSD, AP 
VSD, CCB. AP 
VSD, AP 
VSD. CCB. AP 
VSD, AP 
AP 
VSD, AP 
AP 
VSD 
AP 
VSD 
AP 
VSD. AP 
VSD, AI’ 
VSD, AP 
VSD. AP 
VSD, AP 
VSD. CCB. AP 
DIU, VSD, AP 
DGX. DIU. AP 
AP 
DIU. VSD 
AP 
DIU. VSD. AP 
20 
20 
20 
m 
20 
20 
20 
m 
20 
20 
5 
20 
20 
20 
m 
m 
20 
20 
20 
Stroke 
cardiac surgery 
VSD. CCB, AP 
AIDS 
AP 
VSD 
AP 
AP 
AP 
Died 
AP 
AF 20 
AA = a~ltia~~hythmic agents; AFib = atrial Iibrillation: AIDS = acquired immune deficiency syndrome; AMI = anterior myocankd %iarhit; AP = 
antiphelet agents; CABG = coronary artery bypass gift surgery; CCB = calcium channel blocking agents; DGX = digoxin, MU = diuretic drags: F = female: 
IiTX = heart hansplaaiion; IDCM = idiopathic dilated cardiomyopathy; IHD = ischemic heart disease; IMI = inferior myocardhl iahhon; M = male; 
NYHA = New Yurk Heart Association I&tional &ss&atioa; SGLVD = Studies of Left &nIricuIar Dy&n&on; VSD = vaso&tors. 
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T* 2. C-s in Leff and Right Ventricular Function D&g the Follow-Up Period in Patients 
ia the Prevention Ann of SOLVD 
Placebo Group (II = 11) Enalaptil Group (n = 19) 
Basehe 1 Year Baseline 1Year 
Heart rate (bea&bia) 18 f 8 792 11 85 f 13 82 = 16 
LVEDP btnt Hg) 21 f a 2428 22 f 7 2228 
LVSP (nun Hg) 135 f 21 132 f 24 13Ok22 129221 
dP/dt- (mm HgM 1,380 f 255 1,322 f 262 L483 f 373 1,443 f 385 
T, (ms) 61 27 5929 55 f 8 60 + 14’ 
LVEDVI (mbm-3 146 * 33 155 = 38* 151 f 31 141 2 28t 
LVESVI (n&m-3 104=27 109zk35 110 f 32 97*27+t 
LVEF (%) 29+4 31 zt 7 28 f 7 32 f 8* 
RVEDVI (ml~m-2) 80+28 82 + 31 I9225 84226 
RVESVI (n&m-*) 46223 45 f 22 412 18 48 + 17 
RVEF (%I 442 16 41 f 9 41 f 10 4426 
*p c 0.65 versus basehe. tp < 0.05, enhpril versus placebo. Data are expressed as mean value -C SD. dP/& = 
maximal iirst derivative of left vettiticular ptzssure; LVEDP = IeR vehadar end&lolic pressure; LVEDVI = leff 
ventricular etmldiastolic vahmte index; LVEF = left ventricular &ction fraction; LVESVI = left ventricular end-systolic 
v&me iadwr; LVSP = IeR ventricular systolic presswe; RVEF = @ht venbicular ejection fraction; RVEDVI = right 
ventricttlar enddiastolic volume index, RVESVI = right ventricular end-systolic volume index, SGLVD = Studies of 
LeffVentrieularDysfunction;T,=time~dcarly~~~~ssurrdecrrase. 
ejection fractions improved slightly in both groups, whereas 
the other variables were almost unchanged. 
Challgesiak?ft VentrlculaFwallstressaudthWness. The 
mean systolic wall stress increased (421 f 113 to 508 + 
109 kdynes/cm2, p =NS) in the placebo group and (459 +- 
178 to 494 f 226 kdynes/cm2, p =NS vs. baseline and vs. 
placebo) in the enalapril group. The mean diastolic wall 
stress also increased in the placebo group (1012 31 to 154 + 
59 kdynes/cm21 p = NS) but tended to decrease in the 
enalapril group (106 f 47 to 95 f 46 kdyneslcm’, p = NS vs. 
baseline, p c 0.1 vs. enalapril vs. placebo). Diastolic wall 
thickness measured on the tine 6hns decreased insignitlcantly 
in both groups (8.5 f 2.5 to 8.3 f 2.9 mm with placebo, 8.3 + 
2.0 to 8.1 f 2.6 mm with enalapril, both p = NS). 
Discudon 
Rogmssivecard&cdilationSah~lanPre.Thedata 
obtained in the placebo group of the prevention arm of 
SOLVD indicated that in patients with severe l ft ventricular 
dysfunction, the left ventricle continued to dilate ven when 
the ejection .fraction appeared stable. Qualitatively, thii 
process was similar in patients with ischemic heart disease 
and in those with idiopathic dilated cardiomyopathy. T e 
data lso conthmed that an angiotensin-converting nzyme 
inhibitor could partially prevent or delay this dilation. The 
rate of ventricular dilation appeared, however, significantly 
slower in asymptomatic patients han in patients with wn- 
restive heart failure (9). Furthermore, in these asymptomatic 
patients, he ejection fraction tended toimprove even in the 
placebo group, whereas inpatients with congestive h art 
faihue, left ventricular dilation was accompanied by a de 
crease inejection traction (9). These obuervations, together 
with the data from many previous reports, allow US to 
suggest the hypothesis depicted in Fiiure 1 to explain the 
average time course of the progression f left ventricular 
dysfunction. 
When large amounts of myocardium : e lost or are poorly 
functional, the ejection fraction decreases and end-diastolic 
volume increases. Before sign&ant myocyte hypertrophy 
has taken place, this increase inend-diastolic d mensions 
should be accompanied by arelative thinning of the wall and 
an increase in systolic wall stress (Fig. 1). As the compen- 
satory remodeling process evolves, the ventricle dilates 
further, but as hypertrophy develops, wall thickness in- 
creases and the ejection fraction may rewver slightly (Fii. 
I). 
Me&a&al versus neurohormo~~al stimu i. In most cases 
of severe l ft ventricular dysfunction, however, the degree 
of hypertrophy is never sufhcient tonormalize l ft ventric- 
ular wall stress. This was confirmed in SOLVD because in 
all patients studied, the systolic and diastolic wall stresses 
were markedly augmented at baseline study (20). There was 
also evidence in these patients, even when they were clini- 
cally asymptomatic, hat several neurohumoral systems 
were chronically activated (21). Thus, because the mechan- 
ical and neurohumoral stimuli for hypertrophy wntinued to 
be activated, the remodeling process continued asslow left 
ventricular dilation in our patients inthe prevention arm of 
the study. During this period, the patient may remain asymp 
tomatic and the ejection fraction may be maintained, prob- 
ably because of new wntractile unit8 in the left ventricular 
walls. The duration of this clinically stable phase probably 
varies from patient o patient and may depend on many 
factors uch as age, size and etiology of the initial damage, 
genetic factors and progression f wronary artery disease. 
During this period, however, the compensation is only 
apparent because a steady state is never achieved. 
JACC Vol. 22, No. 4 (Supplement A) 
October I993:43A-8A 
POULEUR ET AL. 
PROGRESSION OF LEFI VENTRICULAR DYSFUiMON 47A 
12 
10 
a 
6 
, 
I 
1 
600 
500 
400 
300 
200 
100 
0 Ejection Fraction 
n Well Thickness 
80 
I 
- Wall stress 
70 
60 
50 
40 
10 
50 100 160 200 250 
EDVI (ml.mq) 
Figure 1. Hypothesis proposed to explain the changes inejection 
fraction (EF), systolic wall stress and wall thickness in relation to 
the progression f the left ventricular dilation (end-diastolic volume 
index BDVIl) after an acute myocardial insult. Under normal 
conditions (first paints on the I&), the ejection fraction is close to 
70% and wall stress is low. Immediately after the insult (second 
pnints), ejection fraction and wall thickness are expected to de- 
crease. Thereafter, jection fraction may recover slightly as a result 
of hypertrophy aswall thickness and end-diastolic volume increase. 
This first phase of remodeling is followed by a period uring which 
end-diastolic volume may increase substantially without deteriora- 
tion in ejection fraction. During this phase, it is postulated that he 
addition of new sarcomeres compensates for the increase inradius 
of curvature (see text). It is believed that most patients in the 
prevention arm of the Studies of Left Ventricular Dysfunction 
(SOLVD) were in this phase. If, however, a stage is reached where 
the rate and extent of dilation exceed the capacity to hypertrophy, 
then ~al.i stress hould start o increase markedly. This is likely b 
cause adecrease in ejection fraction and a rapid eterioration f the 
clinical status (arrow). The patients inthe treatment arm of SOLVD 
appeared tohave reached such a stage of evolution. Although some 
difference may exist at the beginning ofthe process as a result of the 
various etiologies of left ventricular dysfunction, the late phase of 
progression appears elatively nonspecific and qualitatively similar 
in all forms of dilated cardiomyopathy. 
Eventually, it seems that the rate of ventricular dilation 
increases and ejection fraction again declines (Fig. 1, arrow). 
This was observed in the patients in the treatment arm of 
SOlLVD (9). It can be speculated that at this time the rate of 
hypertrophy no longer keeps pace with the rate of dilation. 
Consequently, the wall thickness does not increase or even 
gets thinner as dilation progresses and wall stress begins to 
increase very rapidly, causing adecrease inejection fraction 
despite further l& ventricular dilation (afterload mismatch). 
The data from the SOLVD prevention arm and from the 
Survival and Ventricular Enlargement (SAVE) study (22) 
indicate that angiotensin-converting enzyme inhibitors can 
significantly delay this progression, thereby delaying the 
development of clinical congestive heart failure. Neverthe- 
less, despite their limitations (small sample size and prob- 
lems in the calculation ofwall stress and the measurement of 
wall thickness in these distorted ventricles), the present data 
seem to indicate that enalapril administration at the dose 
used in this study was unable to normalize systolic and 
diastolic wall stress. Thus, the left ventricle remained inan 
unstable state because these stimuli for remo&liog were still 
triggered (1,2). 
For an optimal resu!t, the decrease in left ventricular 
volume induced by enalapril should have been accompanied 
by an increase in wall thickness, which would have allowed 
wall stress to significantly decrease. An abrupt reduction i
ventricular volume is always accompanied byan increase in
wall thickness and a decrease in wall stress, because wall 
mass remains constant. This was not the case in the patients 
in the enalapril group; instead of increasing, wall thickness 
tended to decrease. In a larger study group (23), wall 
thickness and wal! mass also seemed to regress after ad- 
ministration of enalapril. This observation is compatible 
with a reduction in hypertrophy after treatment with an 
angiotensin-converting enzyme inhibitor. Accordingly, the 
long-term effects of angiotensin-converting enzyme inhibi- 
tors on the progression of left ventricular dysfunction are 
complex because they appear to interfere with the adaptive 
process of hypertrophy. In theory, the best possible inter- 
vention should somehow preserve hypertrophy (because 
additional sarcomeres are needed to compensate forthe loss 
of myocardium) while keeping the left ventricular volume as 
small as possible. To produce a greater benefit in terms of 
prevention, it is therefore possible that additional fterload 
reduction, allowing systolic wall stress to decrease, might be 
necessary. In this respect, he effects of enalapril on systolic 
pressure were negligible in these patients. Thus, further 
studies exploring the effects on remodeling of higher doses of 
angiotensin-converting enzyme inhibitors or the combina- 
tion of angiotensin-converting enzyme inhibitors with other 
vasodilators appear justified on the basis of these observa- 
tions. 
Finally, the importance of the mechanical stimuli versus 
that of the neurohumoral stimuli was stressed inthis study 
by the absence of diion of the right ventricle, although the 
myocardium was also exposed to circulating hormones. 
Conclusions. In asymptomatic patients with severe lefi 
ventricular dysfunction, there was a slow progression f the 
left ventricular dilation. Angiotensin-converting enzyme in- 
hibitors appeared tobe capable of slowing this progression. 
However, at the dose used in this study, enahquil did not 
normalize wall stress, suggesting that the benefit of this 
therapy might be limited in some patients. 
We thank Jean Etienne. Henri Van Mechelen a d Alaia Ries for technical 
a&tance: we also thank Sylvie Ahn for adminimtive help and Isabelle 
Mottard and Murielle Duranc for careful sec~a&d assistance. 
References 
1. Pfe&r MA, Braunwald E. Ventricular remode& after my& 
infarction: experimental observations and clinical impkcations. Circula- 
tion 19w;81:1161-72. 
2. Mitchell GF. Pfe5er MA. Left ventricular remodeling after myocardial 
Muction: progression toward Lcart failure. Heart Failure 1992;8:55-69. 
3. Litwin SE, Grossman W.Mechanisms leading ti the development of 
48A POULEUR ET AL. JACC Vol. 22, No. 4 (Supplement A) 
PRtXRRSSION OF LEFl’ VENTRICULAR DYSFUNCTlON October 1993:43A-SA 
hem-t hilure in prcssurc-overhad ypertruphy. Hea Failure 1992;8:48- 
54. 
4. Pouletu H. htnedk and delayed mechanisms of cardiac adaptation to 
a haemodynamic overload. In: Swyt&dauw B. ed. Cardiac Hypertro- 
phy and Failure. Paris, INSERMIJ: Libbey Eurotext, 1990:401-13. 
5. Pfetfer JM. PfeIfer MA, Braumvald E. Inlluence of chronic aptofl 
therapy on the infarcted left ventricle of the rat. Circ Res 1985;57%4-95. 
6. PfcRcr MA, Lamas GA, Vaughan DE, Pstisi AF, Braunwald E. Effect of 
capn@ on prqgressive ntricular dilatation aRer anterior myocaroial 
i&c&m. N l&l J I&d 1988319:80-6. 
7. McKay RG, PfeEer MA. Pa&err& RC. et al. Left ventricuiar remodeling 
after myocsrdiai ntbrction: a coroliary to infarct expansion. Circulation 
1986;74:693-702. 
8. Pouleur II, van Eyll C. Hanet C, Cheron P, Charlier AA, Rousseau MF. 
L,on@erm effects of xamoterol n left ventticnlar hmction and late 
remodeling: a study in patients witb anterior qyocatdial infarction and 
sit&e-vessel disease. Circulation 1988;n: 10814. 
9. Konstam MA, Rousseau MF’, Kronenberg MW. et al. ERects of the 
angiotensin convertin&t enzyme inhibitor enaiapril on the long-term pro- 
lpessIon of let? ventricular dysfunction i patients with heart kibue. 
Ciiatkm 1992~431-8. 
10. The SOLVD Investigators. Studies of Left Ventricular Dystitnction 
(SOLVD)-rationale. de&n and methods: two trials that evahtate he 
e&t ofenalaprR in patients with reduced ejection fraction. Am J Cardiol 
1990,66:315-22. 
11. The SOLVD Investigators. ElTect of enalapril on survival in patients with 
reduced left ventricular ejection Raction and congestive h art failure. 
N Et@ J Med 1991;325:29>392. 
12. The SOLVD Investi8ators. Bflect of enalapril on mortality and the 
development of heart failure in asymptomatic patients with reduced left 
venwicular r&&on f&tions. N Et@ J Med 1992,327:685-91. 
13. Komtam MA, Kronenberg MW, Udelson JE, et al. Effect of acute 
an8iotensin converting enzyme inbiiition on left ventricular filling in 
patients with congestive h art bihue: relation to ri8ht ventricolar vol- 
umes. circuIation 199011:11%2. 
14. Rousseau MF, Gum6 0. van EyB C, Benedict CR, Pouleur II. Effects of 
benaxepriiat on lei? ventricular systolic and diistolic function and neuro- 
Cumoral status in patients with ischemic heart disease. Circulation 
1990;81(suppl III):III-IM. 
15. van EyU C, Gum6 0, Rousseau MF, Etienne J, Chariiir AA, Pouleur H. 
Digital angiogmphy: an open-system dedicated to left ventricular function 
studies. In: Computers in Cardiology. Seattle, Washbgton: IEEE Com- 
puter Society, 1988z417-20. 
16. Rousseau MF, Veriter C, D&y JR, Brasseur LA, Pouleur Ii. Impaired 
early left ventricular relaxation i coronary artery disease: ffects of 
intracoronary nifedipine. Circulation 198@62:764-72. 
17. van Eyll C. Rousseau MF, Pouleur H, Charlier AA, Brasseur LA. 
A&orithms for wall motion analysis: importance of data smoothing and 
correct determination of end-systole. In: Computers in Cardiology. Seat- 
tle, Washington: IEEE Computer Society, 1982~413-6. 
IS. Mirsky I. Elastic properties of the myocardium: a quantitative approach 
with physiol~cal and clinical applications. In: Berne RM, Sperelakis N.
eds. Handbook of Physiology, The Cardiovascular System, Vol. 1. The 
Heart. Baltimore: Williams & Wiikins, 1979:497-531. 
19. Konstam MA, Kronenber8 MW, Rousseau MF. et al. LonRtcrm effects 
of enalapril on left ventricular dilatation i asymptomatic patients with 
reduced ejection fraction: comparison with symptomatic patients (abstr). 
Ciilation 1992$6:9%. 
20. Pouleur H, Rousseau MF, van Eyll C. et al. Cardiac mechanics during 
development of heart failure. Circulation 1993;87(suppl IV):IV-M-20. 
21. Francis GS. Benedict CR, Johnstone DE, et al. Comparison f neuroen- 
doaine activation i patients with left ventricular dysfunction with and 
without congestive heart failure: a substudy of the Studies of Left 
Ventricular Dysfxtction (SOLVD). Ciitdation 1990,82:1724-9. 
22. Pfeiyer MA, Braunwald E, Moyd LA, et al. Effect of captoprii on 
mortality and morbidity inpatients with left ventricular dysfunction after 
myocardKi infarction. N Engl I Med 1992327~669-77. 
23. Greenberg B, Quinones M, Koilpillai C, et al. Effects of long-term 
enalapril therapy on echocardiogmpbic variables in SOLVD patients 
(ebstrl. Circulation 1992$6:997. 
